Novo Nordisk

COPENHAGEN (Reuters) - Danish diabetes and obesity drug developer Novo Nordisk expects to generate sales growth in local currencies of between 13% and...

A new 12-month share repurchase programme of up to 28 billion crowns has been initiated, the company said. The firm will propose a dividend of 8.15 crowns per share, making the total dividend for 2022 12.4 crowns per share. “We are very pleased with the double-digit sales growth in 2022 driven by our innovative GLP-1-based diabetes and obesity treatments,” Chief Executive Lars Fruergaard Jorgensen said in a statement.

Lifted by sales of diabetes and obesity treatments, Denmark's Novo Nordisk, the world's leading insulin company, on Wednesday reported a 16 percent rise in ...

In the overall diabetes treatment sector, Novo Nordisk has market share of 31.9 percent compared to 30.1 percent a year earlier. Type 2 diabetes treatments like Rybelus and Ozempic are among the company's best sellers, with Rybelus seeing a 114 percent increase in sales and Ozempic a 61 percent increase in 2022. Lifted by sales of diabetes and obesity treatments, Denmark's Novo Nordisk, the world's leading insulin company, on Wednesday reported a 16 percent rise in net profit for 2022.

Operating profit increased by 28% in Danish kroner and by 15% at constant exchange rates (CER) to DKK 74.8 billion. Sales in North America Operations increased ...

- Obesity care sales grew by 101% in Danish Kroner (84% at CER). Lars Fruergaard Jørgensen, president and CEO: "We are very pleased with the double-digit sales growth in 2022 driven by our innovative GLP-1-based diabetes and obesity treatments, and more than 36 million people living with diabetes are now benefiting from our treatments. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Rare disease sales increased by 7% measured in Danish kroner (1% at CER). - For the 2023 outlook, both sales and operating profit growth are expected to be 13-19% at CER. The expected total dividend for 2022 is DKK 12.40 per share, of which DKK 4.25 was paid as interim dividend in August 2022.

Never miss a trade again with the fastest news alerts in the world! This headline only article is a sample of real-time intelligence Benzinga Pro traders ...

- Option trade alerts - Fatest intelligence & alerts - The most trusted brand in stock market news

reported Q4 FY22 sales of DKK 48.09 billion, up 25% Y/Y (+18% on constant currency), driven by Diabetes care sales growth of 14% (CER) and Obesity care sales ...

- Novo Nordisk will propose a dividend of 8.15 crowns per share, making the total dividend for 2022 DKK 12.4 per share. - The company expects to invest around DKK 25 billion in 2023, mainly toward additional ingredient production and - Sales of the company's new obesity drug, Wegovy, grew over 200% to DKK 2.5 billion despite - Operating profit increased from DKK 13.64 billion to DKK 17.09 billion, but the margin remained unchanged at 35% from a year ago. - Outlook: Novo Nordisk expects sales and operating profit growth in local currencies in 2023 to be between 13% and 19%. - Net profit increased from DKK 10.89 billion to DKK 13.59 billion.

While Ørsted will divvy up 5.7 billion kroner, Novo is going to hand out 14.8 billion – not bad for shareholders who shared 7.5 billion last August. Handy sale ...

Meanwhile, a post-tax profit of 55.5 billion kroner on sales of 177 billion – a 26 percent increase on 2021 – has prompted Novo Nordisk to predict growth of 13-19 percent for 2023. Energy giant Ørsted, which has almost completely weaned itself off gas (the Dong Energy Days) to concentrate solely on renewables, has announced a record operating profit of 32 billion kroner for 2022 – a substantial increase on the 7.8 billion declared in 2021. Shareholders in Ørsted and Novo Nordisk have much to rejoice today, as both companies have decided to issue big dividends following the declaration of record profits.

Novo Nordisk A/S forecast earnings will rise this year to record levels, boosted by soaring demand for its Wegovy obesity drug.

Lifted by sales of diabetes and obesity treatments, Denmark's Novo Nordisk, the world's leading insulin company, on Wednesday reported a 16 percent rise in ...

In the overall diabetes treatment sector, Novo Nordisk has market share of 31.9 percent compared to 30.1 percent a year earlier. Type 2 diabetes treatments like Rybelus and Ozempic are among the company's best sellers, with Rybelus seeing a 114 percent increase in sales and Ozempic a 61 percent increase in 2022. Lifted by sales of diabetes and obesity treatments, Denmark's Novo Nordisk, the world's leading insulin company, on Wednesday reported a 16 percent rise in net profit for 2022.

By Dominic Chopping Novo Nordisk AS reported results for the fourth quarter on Wednesday. Here's what we watched: NET PROFIT: Net profit in the fourth...

Novo Nordisk said it expects growth of GLP-1-based treatments for diabetes and obesity care, partially countered by declining sales in rare disease, intensifying competition, pricing pressure within diabetes care and periodic supply constraints. Reported growth in sales is seen around four percentage points below local currencies, while reported operating profit growth is seen around five percentage points lower. Novo Nordisk's GLP-1 drugs saw a 49% increase in fourth-quarter sales to DKK24.35 billion while sales of its Wegovy weight-loss injectable drug rose to DKK2.45 billion from DKK782 million. --MARGINS: The gross margin fell to 82.8% in the fourth quarter from 83.7% last year. --GUIDANCE: The company said it expects 2023 sales and operating profit growth of 13%-19% in local currencies. and China and a negative currency impact.

BAGSVAERD, Denmark (AP) _ Novo Nordisk A/S (NVO) on Wednesday reported fourth-quarter net...

On a per-share basis, the Bagsvaerd, Denmark-based company said it had profit of 83 cents.

Novo Nordisk (NVO) (NONOF) Q4 revenue grew on the back of Diabetes and Obesity care sales while insulin segment sales saw a decline.

Total Obesity care segment sales increased +123% Y/Y (+105% CER) to DKK5.49B. Dividend: The company said that at the Annual General Meeting on March 23, the board will propose a final dividend of DKK 8.15 for 2022 per share. Operating margin was 35.5%, compared to 35.6% in Q4 2021. Net profit increased +25% to DKK13.59B. Q4 Rare disease segment sales grew +3% Y/Y (-2% CER) to DKK4.85B. Blockbuster drugs Ozempic (semaglutide) sales rose (+45% at CER) Y/Y to ~DKK16.98B, Rybelsus revenue increased (+105% at CER) Y/Y to DKK4.05B.

Novo Nordisk (NVO) (NONOF) Q4 revenue grew on the back of Diabetes and Obesity care sales while insulin segment sales saw a decline.

Total Obesity care segment sales increased +123% Y/Y (+105% CER) to DKK5.49B. Dividend: The company said that at the Annual General Meeting on March 23, the board will propose a final dividend of DKK 8.15 for 2022 per share. Operating margin was 35.5%, compared to 35.6% in Q4 2021. Net profit increased +25% to DKK13.59B. Q4 Rare disease segment sales grew +3% Y/Y (-2% CER) to DKK4.85B. Blockbuster drugs Ozempic (semaglutide) sales rose (+45% at CER) Y/Y to ~DKK16.98B, Rybelsus revenue increased (+105% at CER) Y/Y to DKK4.05B.

Novo Nordisk (NVO) reports mixed results for Q4 as earnings beat estimates but sales miss on the same. Sales are aided by growth in Diabetes and Obesity ...

During the same period, the earnings estimate per share for 2023 has increased from $4.24 to $4.41. During the same period, the loss estimate per share for 2023 has narrowed from $2.00 to $1.77. In the past 90 days, the estimate for Sanofi’s 2022 earnings per share has increased from $4.04 to $4.32. During the same period, the loss estimate per share for 2023 has narrowed from $1.68 to $1.30. The guidance also reflects the sales growth of Wegovy in the United States upon meeting the demand in 2023. In the past 90 days, the estimate for Cabaletta’s 2022 loss per share has narrowed from $1.89 to $1.76. In the past 90 days, the estimate for LianBio’s 2022 loss per share has narrowed from $1.65 to $1.23. Sales and distribution costs climbed 18% in DKK and increased 11% at CER year over year. Rybelsus too witnessed a strong uptake and recorded sales of DKK 4.05 billion for the quarter, up 105% at CER. Ozempic is off to a solid start and the launch of Rybelsus looks encouraging. Sales of hemophilia A products increased by 6% at CER. Novo Nordisk A/S( NVO Quick Quote NVO - Free Report) reported fourth-quarter 2022 earnings of 83 cents per American Depositary Receipt, which beat the Zacks Consensus Estimate of 81 cents.

Bloomberg's Joe Easton has a rundown of the stocks to keep an eye on today, including pharmaceutical firms Novartis, Novo Nordisk and GSK, Spanish bank BBVA ...

NVO earnings call for the period ending December 31, 2022. Logo of jester cap with thought bubble. Image source: The Motley Fool. Novo Nordisk A/s ...

And then, it's, in the U.S., up to Doug and his team to discuss with payers and others on how that will impact the dynamics. And as we just discussed before, we remain very confident in the efficacy and safety profile of icodec that given as a once-weekly insulin. So, as you know, normally, for '24 -- then we give the [Inaudible] of scripts, and then there will be true-ups normally in Q4 that can impact the value to volume equation. Of course, looking forward, that means that we expect that there is a potential for both of these two classes to coexist and to continue increasing as we see both unexploited potential for GLP-1 treatment in diabetes, as well as in obesity. We see -- we are back to TRx and NBRx leadership. So, based on the totality of the data that you just went through and from the total ONWARDS program, we are very confident in the efficacy and the safety profile of once-weekly icodec and also the potential to become standard-of-care insulin of choice for people with Type 2 diabetes. So, this focus of the extension is safety assessment and establishing the long-term safety profile of insulin icodec in both Type 1 and Type 2 diabetes. And in the 52-week period of the ONWARDS 1 study, as you know, we showed a superior A1c reduction with a good and flat and stable -- sorry, hypoglycemia profile. And we have one line on track to be online first half of this year and then another line on track to get online second half this year. And it comes from the line of Peter Verdult from Citi. We are very pleased with double-digit sales growth for the full year of 2022 and that we continue to reach even more patients. Welcome to Novo Nordisk's earnings call for the full year of 2022 and the outlook for 2023.